News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018

Hypofractionated patients showed similar PSA control and overall survival with nearly three weeks less of radiation therapy

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation

October 31, 2018 — An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with hypofractionated intensity modulated radiation therapy (HIMRT) yields equivalent disease outcomes compared with conventional intensity modulated radiation (CIMRT). It is the largest randomized single-institution study with the longest follow-up period on this topic to date.

The study enrolled 300 men and followed them over a median period of 11 years after treatment. Half had received H-IMRT and half had received C-IMRT. Men in both groups also received standard-of-care androgen deprivation therapy (ADT) when it was indicated. H-IMRT delivers more radiation per treatment session, allowing patients to complete treatment over a much shorter period than C-IMRT (5 ½ weeks versus 8 weeks). Advantages include fewer medical appointments, lower costs and more efficient utilization of clinical resources.

Vladimir Avkshtol, M.D., a radiation oncology resident at Fox Chase, presented the results at an oral session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

At five years and 10 years after treatment, men who had received either form of therapy showed similar results on several measures, including prostate-specific antigen (PSA) control and overall survival. There was initially some cause for concern over a trend toward higher rate of developing metastases in men in the H-IMRT group; however, this was not statistically significant and no subset of patients seemed to be at higher risk on further analysis.

“Our analysis shows that for most men with localized prostate cancer, H-IMRT is a viable option and should be considered for most men. Our study is one of the biggest and most mature studies of its kind in the U.S.,” said Avkshtol.

Read more about late-breaking clinical trials presented at ASTRO 2018.

For more information: www.astro.org


Related Content

News | ASTRO

July 9, 2025 — The American Society for Radiation Oncology (ASTRO) selected 43 members to receive the ASTRO Fellow ...

Time July 09, 2025
arrow
Feature

A new study published in JCO Clinical Cancer Informatics tackles a critical challenge in cancer diagnostics: ensuring ...

Time July 01, 2025
arrow
News | Radiation Therapy

June 12, 2025 — According to a new report published in the American Society of Radiation Oncology journal, Practical ...

Time June 12, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Subscribe Now